全部1.476亿美元可兑换债券,按每股0.60至0.80美元兑换成2.6M股。 All $1.476M in convertible debentures converted into 2.6M shares at $0.60–$0.80 per share.

2025年11月21日,国防治疗公司宣布,其8%可兑换债券的所有持有者于2024年11月16日公布,将147 600万美元的本金和应计利息转换为到期时的2 607 600份共同股份。 Defence Therapeutics Inc. announced on November 21, 2025, that all holders of its 8% convertible debentures, issued November 16, 2024, converted the $1.476 million principal and accrued interest into 2,607,600 common shares upon maturity. 转换时本金按每股0.60美元,利息按每股0.80美元计算。 The conversion occurred at $0.60 per share for principal and $0.80 per share for interest. 该公司利用其ACCUME平台开发有针对性的癌症治疗,称全面转换反映了投资者的信心。 The company, which develops targeted cancer therapies using its ACCUM® platform, said the full conversion reflects investor confidence. 股票列在CSE、FSE和OTCQB上。 The shares are listed on the CSE, FSE, and OTCQB.